<DOC>
	<DOCNO>NCT00921375</DOCNO>
	<brief_summary>This study prospective , open-label , multicentre study . Hundred eligible patient stage III IV non-Hodgkin lymphoma ( NHL ) acute lymphoblastic leukemia ( ALL ) peripheral white blood cell ( WBC ) count &gt; 25,000/µL leukemia lymphoma plasma uric acid level least 8 mg/dL treat rasburicase 0.20 mg/kg body weight intravenously 4 day . The primary endpoint viz. , percentage reduction plasma uric acid 4 hr uric acid-lowering therapy , plasma uric acid AUC 0-96 hr incidence adverse event assess 11 day study period .</brief_summary>
	<brief_title>Safety Efficacy TULY ( Rasburicase ) Prevention Treatment Malignancy-associated Hyperuricemia</brief_title>
	<detailed_description>All eligible patient treat rasburicase 0.20 mg/kg body weight intravenously 4 day . The primary endpoint viz. , percentage reduction plasma uric acid 4 hr uric acid-lowering therapy , plasma uric acid AUC 0-96 hr incidence adverse event assess 11 day study period .</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>1 . Patients gender age 1 75 year ; 2 . Patients stage III IV nonHodgkin lymphoma ( NHL ) acute lymphoblastic leukemia ( ALL ) peripheral WBC count &gt; 25,000/µL leukemia lymphoma plasma uric acid level least 8 mg/dL ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance scale ≤3 ; 4 . Patients schedule receive chemotherapy . 1 . Patients allergy asthma , hypersensitivity urate oxidase , hemolytic reaction ; 2 . Pregnant lactating ; 3 . Patients glucose6phosphate dehydrogenase deficiency ; 4 . Exposure rasburicase allopurinol within 7 day ; 5 . History psychiatric comorbid unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>